Showing results (1211-1220 of 2,642) with videos related to

Sort By:
Pageof 265
Hematology (Amsterdam, Netherlands)|February 6, 2024
Clinical features and prognosis of chronic natural killer cell lymphoproliferative disordersDong-Lin Liu, Yan-Jie Wang, Si-Yu Qian, et al.
Hematology (Amsterdam, Netherlands)|February 7, 2024
Clinical features and outcomes of patients with acute myeloid leukemia: the single-center experience of 668 patients in ChinaJie Ding, Yang Su, Yinglu Ruan, et al.
Hematology (Amsterdam, Netherlands)|February 9, 2024
More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?Moisés Manuel Gallardo-Pérez, César Homero Gutiérrez-Aguirre, Juan Carlos Olivares-Gazca, et al.
Hematology (Amsterdam, Netherlands)|February 1, 2024
Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatmentYi-Gang Guo, Lu-Lu Zhang, Ping Hu, et al.
Hematology (Amsterdam, Netherlands)|March 28, 2024
Distinguishing thrombotic thrombocytopenic purpura from primary immune thrombocytopenia accompanied by anemia using the carbon monoxide breath testXiaoyan Tan, Yan Shen, Yu He, et al.
Hematology (Amsterdam, Netherlands)|April 3, 2024
Identification of HIST1H2BH as the hub gene associated with multiple myeloma using integrated bioinformatics analysisWenxue Zhang, Xian Chen, Zhe Wang, et al.
Hematology (Amsterdam, Netherlands)|April 3, 2024
Lesson learned in pediatric haploidentical transplantation in a low-resource environment: delivering melphalan IV and using low dose radiation reduce graft failureValentine Jiménez-Antolinez, Julia Colunga-Pedraza, Andrés Gómez-De León, et al.
Hematology (Amsterdam, Netherlands)|March 25, 2024
Endari treatment ameliorates sickle cell-related disruption in intestinal barrier functions and is associated with prolonged survival in sickle cell miceElio Haroun, Seah H Lim, Dibyendu Dutta
Hematology (Amsterdam, Netherlands)|March 15, 2024
Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patientsXiaoqing Dong, Ruoyi Wang, Xiuhua Ying, et al.
Hematology (Amsterdam, Netherlands)|March 21, 2024
PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patientsHongyu An, Shiming Chen, Xin Zhang, et al.
Pageof 265